ImmuPharma, Avion Agree to Continue Lupus Program; Explore Distribution Agreement
November 11 2022 - 4:00AM
Dow Jones News
By Kyle Morris
ImmuPharma PLC said Friday that its U.S. partner Avion
Pharmaceuticals LLC has agreed to continue its support of the
clinical program of Lupuzor for lupus and that the companies will
explore a distribution agreement to introduce certain Avion
products into the European market.
The pharmaceutical company said the Lupuzor for Lupus clinical
program is to be redesigned on key protocols in order to enhance
the probability of success after a written response from the U.S.
Food and Drug Administration.
The distribution agreement has the potential for product sales
revenues for ImmuPharma, it said.
Shares in ImmuPharma at 0826 GMT were up 0.29 pence, or 8.9%, at
3.60 pence.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
November 11, 2022 03:45 ET (08:45 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024